The U.S. Food and Drug Administration (FDA) must act to protect Americans from fake versions of GLP-1 weight loss and diabetes drugs such as Ozempic and Mounjaro and take “decisive action” against bad actors engaged in such trade, a letter from a bipartisan coalition of attorneys general from 38 U.S. states said.
“My fellow attorneys general and I are urging the FDA to protect consumers from the growing threat posed by adulterated or counterfeit versions of these drugs,” California Attorney General Rob Bonta, a signatory of the letter, said in a Feb. 20 statement.
“From inspections to enforcement actions, the FDA has several important tools at its disposal to help put an end to this unlawful and deceptive conduct. A federal response is necessary because many of the counterfeit drugs are shipped from outside of the country.”…